

# A Study of TIL in Advanced Solid Tumors (DFGD)

NCT06488950

---

Status	RECRUITING
Phase	Early Phase 1
Sponsor	Shanghai Juncell Therapeutics
Enrollment	30 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- have one the tumor resection for TILs production and successfully produced
- Age: 18 years to 75years;
- Histologically diagnosed as solid tumors;
- Expected life-span more than 3 months;
- ECOG score 0-1;
- ... and 2 more (see full listing online)

### Exclusion (5)

- with other malignant tumors, except for the malignancies that have been cured, have been inactive for e5 years prior to study inclusion and have a very low risk of recurrence; Non-melanoma skin cancer or malignant lentigo with adequate treatment and no evidence of disease recurrence; Carcinoma in situ with adequate treatment and no evidence of disease recurrence;
- Need glucocorticoid treatment, and daily dose of Prednisone greater than 10mg(or equivalent doses of hormones) or autoimmune diseases requiring immunomodulatory treatment;
- Breathe indoor air in a quiet state, and the oxygen saturation of finger pulse is  $\leq 95\%$ ;
- Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;
- Significant cardiovascular anomalies

## Locations (1 total)

---

Third Affiliated Hospital of Naval Medical University, Shanghai, China